Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Lupus Erythematosus (SLE): early-phase trial registry
10 of 15 indexed Systemic Lupus Erythematosus (SLE) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 10 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Systemic Lupus Erythematosus (SLE): 15 US clinical trials tracked, 10 recruiting.
Systemic Lupus Erythematosus (SLE) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.
Enrollment posture brief
Registry condition systemic-lupus-erythematosus-sle
OPEN 10 | RECR 67% | LATE 2 | EARLY 8 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Systemic Lupus Erythematosus (SLE) lists 10 open slots (67% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Lupus Erythematosus (SLE) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Lupus Erythematosus (SLE) is recruiting above its size-band peers.
10 of 15 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Systemic Lupus Erythematosus (SLE) trials is spread across many organizations.
Bristol-Myers Squibb accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Systemic Lupus Erythematosus (SLE) enrolment sits around 100 participants.
Median target enrolment is 100 among the 15 trials that report a genuine target (sentinel values excluded). 7 of those (46.7%) plan for fewer than 100 participants.
-
Systemic Lupus Erythematosus (SLE) research is mostly interventional.
11 interventional and 4 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Research Accelerated by You Lupus Registry
Lupus Foundation of America
NCT06927219
Lupus Landmark Study: A Prospective Registry and Biorepository
Lupus Research Alliance
NCT05934149
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Fate Therapeutics
NCT06308978
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Bristol-Myers Squibb
NCT07175285
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
DualityBio
NCT06625671
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT05567198
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
National Heart, Lung, and Blood Institute (NHLBI)
NCT06032923
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Bristol-Myers Squibb
NCT06875960
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Children's Hospital of Philadelphia
NCT06839976
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
LiveKidney.Bio
NCT06737380
Descartes-08 for Patients With Systemic Lupus Erythematosus
Cartesian Therapeutics
NCT06038474
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
Amgen
NCT04058028
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
UCB Biopharma S.P.R.L.
NCT02804763
CCCR Lupus Patient Navigator Program
Medical University of South Carolina
NCT04461158
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Mallinckrodt
NCT01753401
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Lupus Erythematosus (SLE) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Lupus Erythematosus (SLE) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Lupus Erythematosus (SLE) page
15 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Systemic Lupus Erythematosus (SLE) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Systemic Lupus Erythematosus (SLE) trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Lupus Erythematosus (SLE) condition card totals 15 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.